ARMP Strangle Strategy
ARMP (Armata Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on AMEX.
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
ARMP (Armata Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $323.1M, a beta of 1.32 versus the broader market, a 52-week range of 1.17-16.34, average daily share volume of 56K, a public-listing history dating back to 1994, approximately 60 full-time employees. These structural characteristics shape how ARMP stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.32 indicates ARMP has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on ARMP?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current ARMP snapshot
As of May 15, 2026, spot at $8.05, ATM IV 209.80%, IV rank 38.08%, expected move 60.15%. The strangle on ARMP below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on ARMP specifically: ARMP IV at 209.80% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 60.15% (roughly $4.84 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ARMP expiries trade a higher absolute premium for lower per-day decay. Position sizing on ARMP should anchor to the underlying notional of $8.05 per share and to the trader's directional view on ARMP stock.
ARMP strangle setup
The ARMP strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ARMP near $8.05, the first option leg uses a $8.45 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ARMP chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ARMP shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $8.45 | N/A |
| Buy 1 | Put | $7.65 | N/A |
ARMP strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
ARMP strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on ARMP. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on ARMP
Strangles on ARMP are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ARMP chain.
ARMP thesis for this strangle
The market-implied 1-standard-deviation range for ARMP extends from approximately $3.21 on the downside to $12.89 on the upside. A ARMP long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current ARMP IV rank near 38.08% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on ARMP should anchor more to the directional view and the expected-move geometry. As a Healthcare name, ARMP options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ARMP-specific events.
ARMP strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ARMP positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ARMP alongside the broader basket even when ARMP-specific fundamentals are unchanged. Always rebuild the position from current ARMP chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on ARMP?
- A strangle on ARMP is the strangle strategy applied to ARMP (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With ARMP stock trading near $8.05, the strikes shown on this page are snapped to the nearest listed ARMP chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ARMP strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ARMP strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 209.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ARMP strangle?
- The breakeven for the ARMP strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ARMP market-implied 1-standard-deviation expected move is approximately 60.15%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on ARMP?
- Strangles on ARMP are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ARMP chain.
- How does current ARMP implied volatility affect this strangle?
- ARMP ATM IV is at 209.80% with IV rank near 38.08%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.